Video Experimental Relacionado
Updated: Aug 16, 2026
12:24
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Desafíos y éxitos en el desarrollo de nuevas terapias para la hepatitis C
Raffaele De Francesco1, Giovanni Migliaccio
1Istituto di Ricerche di Biologia Molecolare P. Angeletti, Via Pontina km 30.600, 00040 Pomezia-Rome, Italy. raffaele_defrancesco@merck.com
Nature
|August 19, 2005
Resumen
El virus de la hepatitis C (VHC) sigue siendo un desafío para la salud mundial debido a las infecciones y enfermedades crónicas. Las nuevas combinaciones de fármacos son esenciales para superar la resistencia al tratamiento y controlar eficazmente el VHC crónico.
Área de la Ciencia:
- Virología Virología.
- Hepatología Hepatología.
- Enfermedades infecciosas Enfermedades infecciosas.
Sus antecedentes:
- La infección por el virus de la hepatitis C (VHC) representa una amenaza significativa y a largo plazo para la salud mundial.
- La infección crónica por el VHC conduce a una morbilidad sustancial de la enfermedad y una alta prevalencia en todo el mundo.
- Los tratamientos existentes y emergentes se enfrentan a limitaciones debido a la posible resistencia a los medicamentos.
Objetivo del estudio:
- Revisar el panorama actual del tratamiento del virus de la hepatitis C (VHC).
- Para resaltar los desafíos planteados por la resistencia a los medicamentos del VHC.
- Hacer hincapié en la necesidad de terapias combinadas en el manejo del VHC crónico.
Principales métodos:
- Revisión de los datos recientes de ensayos clínicos de prueba de concepto para nuevas moléculas antivirales.
- Análisis de la evidencia preclínica con respecto al desarrollo de resistencia a los medicamentos en el VHC.
- Síntesis de los conocimientos actuales sobre la patogénesis del VHC y las estrategias de tratamiento.
Principales resultados:
- Los agentes antivirales emergentes son prometedores en las primeras etapas de los ensayos clínicos.
- Los estudios preclínicos indican una creciente preocupación por el desarrollo de resistencia contra los nuevos medicamentos para el VHC.
- Es probable que la eficacia a largo plazo de las monoterapias se vea comprometida por la resistencia.
Conclusiones:
- La terapia de combinación con múltiples agentes es crucial para el tratamiento eficaz de la infección crónica por el virus de la hepatitis C.
- Abordar la resistencia a los medicamentos es una consideración clave para los futuros regímenes de tratamiento del VHC.
- Se necesitan esfuerzos sostenidos para combatir la carga de salud mundial del VHC.
Videos de Conceptos Relacionados
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:29Microorganisms in Medicine and Therapeutics
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...